Intercept Pharmaceuticals, Inc. (ICPT)
-NasdaqGM 38.41 
5.40(16.36%) 4:00PM EDT|After Hours
:
38.41 0.00 (0.00%) 4:32PM EDT
| Prev Close: | 33.01 |
|---|
| Open: | 35.05 |
|---|
| Bid: | 37.00 x 200 |
|---|
| Ask: | 38.50 x 200 |
|---|
| 1y Target Est: | 51.00 |
|---|
| Beta: | 0.17 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 35.00 - 38.47 |
|---|
| 52wk Range: | 17.96 - 42.67 |
|---|
| Volume: | 989,434 |
|---|
| Avg Vol (3m): | 35,150 |
|---|
| Market Cap: | 645.48M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -5.53 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage increasesAP(Wed 6:06PM EDT)
- Nasdaq stocks posting largest volume increasesAP(Wed 6:05PM EDT)
- Intercept Pharmaceuticals Announces Pricing of Public Offering of Common StockPR Newswire(Tue, Jun 18)
- 5 Undervalued Stocks Flying Under The Radar!at Forbes(Tue, Jun 18)
- Intercept Pharmaceuticals Announces Proposed Public Offering of Common StockPR Newswire(Mon, Jun 17)
- IC Potash Receives Jurisdictional Determination From U.S. Army Corps of Engineers for Ochoa Potash ProjectMarketwired(Tue, Jun 11)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Fri, May 31)
- IC Potash Adopts Advance Notice to By-LawsMarketwired(Wed, May 29)
- Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare ConferencePR Newswire(Thu, May 23)
- Are These Top Post-IPO Performers Still a Buy?at Motley Fool(Wed, May 22)
- IC Potash Issues Progress Update on Ochoa Sulphate of Potash Project in New MexicoMarketwired(Wed, May 22)
- INTERCEPT PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid DiarrheaPR Newswire(Mon, May 20)
- Top Life Science Investors Of 2013at Forbes(Thu, May 9)
- Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASLGlobeNewswire(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 265.07 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.24 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.52 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry.
View More